Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bristol Readies Saxagliptin Launch In Anticipation Of FDA Approval

Executive Summary

Bristol-Myers Squibb expects its next launch, diabetes drug Onglyza, along with its expanding string of "pearls" - partnership deals - will place the firm in a superior position to offset generic losses in 2012

You may also be interested in...



BMS CEO Jim Cornelius to Retire; Andreotti Named CEO

Lamberto Andreotti, currently president, was the front-runner in a year-long, three-way race to replace Cornelius.

Bristol/AZ Saxagliptin Safety Review: All Signs Point to Positive Committee Outcome

Upcoming FDA advisory committee review of DPP4 inhibitor poses first test of new diabetes cardiovascular safety guidelines. Bristol and AstraZeneca won’t be the only companies watching carefully.

Last Gasp Or New Life? 2009’s Novel Products Have Blockbuster Potential

After a 2008 NME approval slate that was heavy on modest specialty products, the 2009 user fee calendar offers the potential for a return of the blockbuster

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS050642

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel